



## The Human Proteome in Disease, Diagnostics and Translation into Precision Medicine: Current Status and Future Prospects

Guest Editor:

### Dr. M. Walid Qoronfleh

1. Q3 Research Institute (QRI),  
Research & Policy Division, Ann  
Arbor, MI 48197, USA  
2. Consulting Services  
Department, 21 HealthStreet,  
London SW16 3JY, UK

Deadline for manuscript  
submissions:

**31 October 2024**

### Message from the Guest Editor

Dear Colleagues,

It gives us great pleasure to invite researchers and scientists to this MDPI Special Issue by *Biomedicines*, which focuses on the human proteome in health, disease and therapy. Proteins are the primary functional effectors in human biology and are involved in health and diseases. The human proteoforms are rich and deciphering their structure/function is critical to both basic and translational research. It is very fitting and timely to launch this Special Issue as we celebrate 20 years of human proteome accomplishments and prepare for the next generation of advancements.

Since the inception of the Human Proteome organization (HUPO) and its first World Congress in November 2002, the stated visionary goal has been translating the code of life. Undoubtedly, this will not only enhance our holistic understanding of human biology at the cellular/molecular levels but will also establish a foundation for the development of diagnostic, prognostic, therapeutic, and preventive medical applications.

For marking the human proteome achievements, this *Biomedicines'* Special Issue aims to contribute to the knowledge of the human proteome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI